A presentation on initial results of patient data from compassionate use of Perspective Therapeutics’ lead preclinical candidate for neuroendocrine tumors being used in India shows extremely encouraging results. https://t.co/IkOHNXVxU4 #cancer#radiotherapy#radiopharmaceuticals
.@Isoray today announced the successful completion of the merger with @Viewpoint_MT. Viewpoint Molecular Targeting, Inc. revealing the combined companies’ new leadership, focus, board of directors, and more. https://t.co/kz6YI2YNC4 #cancer#radiotherapy#radiopharmaceuticals
Did you watch #Isoray CEO Lori Woods with Proactive financial media discussing the Isoray merger with Viewpoint Molecular Targeting, Inc. and the big opportunity it represents in 2023? https://t.co/DGwGbGVwb9 #oncology#Radiopharmaceuticals#radiation#Radiotherapy#cancer